Carcinoma Transitional Cell clinical trials

Explore recruiting carcinoma transitional cell clinical trials.

Recruiting carcinoma transitional cell studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Carcinoma Transitional Cell trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.

Italy, Poland, Denmark, Czechia, France, Hungary +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Cancer

Spain, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

Carcinoma Transitional Cell trials by city

Carcinoma Transitional Cell clinical trials

Recruiting carcinoma transitional cell studies right now

Urine Methylation Markers in UTUC

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

Chemoablation for Low-Grade Bladder Cancer

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients

Also recruiting in Europe

J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Cancer

Carcinoma Transitional Cell trials by city

Other conditions